Home › Ulcerative Colitis › NCT05218850
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RecruitingPhase 2
Butyrate Therapy in Hispanic Children With Ulcerative Colitis
Who can join
Ages 7 to 21 · All sexes
Full eligibility criteria
Inclusion Criteria: * 7-21 years, mild to moderate ulcerative colitis Exclusion Criteria: * UC therapy within 4 weeks of study medication initiation * infectious colitis, -pregnancy
About the study
Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.
What is being tested
- Butyrate (drug)
Sponsor: Children's Hospital Los Angeles · Participants: 10 · Started: Jun 29, 2022
Contact the study team
- Sonia Michail, MD · Phone: 3233611353
Official record on ClinicalTrials.gov — NCT05218850
Locations in the U.S.
| California | Children's Hospital Los Angeles, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.